Background: Parkinson's disease (PD) is the most common neurodegenerative disease after Alzheimer's dementia. Whereas the exact etiology of PD remains unknown, risk of developing PD seems to be related to a combination of genetic and environmental factors. This also includes abnormal exposure to trace elements of nutritional and toxicological interest. Objectives: In this systematic review and metaanalysis, we summarized the results of case-control studies comparing levels of selenium, copper, iron, and zinc in PD patients and controls in either blood (whole blood, serum/ plasma) or cerebrospinal fluid (CSF). Methods: We performed a systematic PubMed search selecting studies reporting trace element levels in different specimens of patients and controls. We performed a meta-analysis using a random-effect model to compute the weighted mean differences (WMD) and corresponding 95% CI of selenium, copper, iron, and zinc levels in the blood or CSF of patients and their matched controls. Results: We retrieved 56 papers reporting data for selenium (cases/controls: 588/721), copper
, iron (2,956/3,469) , and zinc (1,798/1,913) contents in CSF and blood. Cases showed considerably higher levels of selenium in CSF compared with controls (+51.6%; WMD 5.49; 95% CI 2.82 to 8.15), while levels in serum were similar (-0.2%; WMD -0.22; 95% CI -8.05 to 7.62). For copper, cases showed slightly higher levels in CSF and slightly lower concentrations in serum (+4.5%; WMD 1.87; 95% CI -3.59 to 7.33, and -4.5%; WMD -42.79; 95% CI -134.35 to 48.76, respectively). A slight increase was also found for CSF iron levels (+9.5%; WMD 9.92; 1.23 to 18.61), while levels were decreased in serum/plasma (-5.7%; WMD -58.19; 95% CI -106.49 to -9.89) and whole blood (-10.8%; WMD -95.69; 95% CI -157.73 to -33.65). Conversely, for zinc cases exhibited lower levels both in CSF (-10.8%; WMD -7.34; 95% CI -14.82 to 0.14) and serum/plasma (-7.5%; WMD -79.93; 95% CI -143.80 to -16.06). A longer duration of the disease tends to be associated with overall lower trace element levels in either CSF or blood. Conclusions: Due to the study findings and the greater relevance of the CSF compartment compared with the circulating peripheral ones, this meta-analysis suggests that overexposure in the central nervous system to selenium, and possibly to copper and iron, may be a risk factor of the disease, while zinc might have a protective effect.
Introduction
Parkinson's disease (PD) is a neurodegenerative disorder with predominantly motor manifestations such as akinesia and bradykinesia, tremor, muscle stiffness, and postural instability [1] . Nonmotor symptoms also exist, including anxiety, depression, and constipation. These clinical manifestations are the result of dopaminergic neuron death. Dopaminergic neurons are cells located in the pars compacta of substantia nigra, a mesencephalic section entrusted with dopamine synthesis and release. PD is recognized as the most common neurological disorder after Alzheimer's dementia [2] . In industrialized countries, the prevalence is approximately 0.3% in the general population, with increasing value in the elderly, that is, 1.0% in people aged ≥60 years, and 3.0% in those aged ≥80 years [1, 3] . Overall, PD annual incidence ranges from 8 to 18 per 100,000 inhabitants, with a male-to-female ratio around 1.5. Since ageing is the most important risk factor, its prevalence and burden are expected to increase over the next decades [1, 4, 5] .
Although the exact cause of PD remains unknown, it seems to be related to interrelation of genetic and environmental factors [6, 7] . For instance, caffeine [3] and in a more controversial way smoking [8, 9] have been suggested as possible protective factors, while exposure to pesticides, especially rotenone and paraquat, derivatives of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, traumatic brain injuries, and occupational exposure to pesticides and heavy metals appear to be detrimental risk factors for the disease [3] . Additionally, alterations in trace element homeostasis have been suggested to play a role in the etiology of PDrelated neurodegeneration. In particular, abnormal levels of some heavy metals and metalloids, such as selenium, copper, iron, and zinc, can adversely affect the nervous system through the induction of reactive oxygen species production [10] [11] [12] . However, the role of selenium and other trace elements is still controversial, and the recent available reviews on the topic are either missing or out-of-date.
We carried out an updated systematic review and meta-analysis, in which we summarized the results of casecontrol studies reporting levels of selenium, copper, iron, and zinc in the blood and cerebrospinal fluid (CSF) of PD patients compared with controls.
Methods

Literature Search
We performed a systematic search in the PubMed/Medline database using the MeSH Terms "PD" and "trace elements" (including individual elements) through July 4, 2019 (Box 1 of Fig. 1 ).
Inclusion criteria were studies carried out in humans, observational design, and reporting levels of selenium, copper, iron, and zinc in either whole blood, serum, plasma, or CSF. Exclusion criteria were studies not carried out in humans, those not having an observational design or not reporting trace element contents, those including cases of Parkinsonism, autoptic studies, studies evaluating levels of elements other than selenium, copper, iron, and zinc, and those carried out in tissues rather than whole blood, serum, plasma or CSF.
Data Extraction
For each study, we extracted the year of publication, country of region and sample size, data about demographic characteristics of cases and controls (i.e., age and sex), and, for cases, disease duration and severity score (Hoehn and Yahr stage of disease [13] ). For each study population, we extracted the trace element levels into a database in different specimens (whole blood, serum, plasma, and CSF), as mean ± SD in µg/L or median and interquartile range, when these were the only available data [14] [15] [16] [17] . When only means or medians with their range were reported, we calculated SD = range/4. When the interquartile range was reported, we computed SD as (Q 3 -Q 1 )/1.35 and, when only 95% CI was reported, we calculated SD as ([95% CI-mean]/1.96] *√n [18] . We converted levels reported in µmol/L into molar mass. When there were > 1 group of cases or controls [19] [20] [21] [22] , we computed a combined weighted mean and SD (online suppl. Table S1 ; for all online suppl. material, see www.karger.com/doi/10.1159/000502357 for detailed methods).
For 1 study [23] , we asked the authors to kindly provide additional data not reported in the paper. Moreover, for a study in which 2 sets of cases and controls were reported [24] , the few patients with longer-duration PD (6.0 ± 4.6 years) and the controls with the lowest age were not included in our analysis, to make cases and controls comparable for age (60.8 and 61.2 years, respectively). Finally, serum selenium levels in 1 study appeared to be entirely implausible due to extremely low values in patients, as it was the case with serum iron levels in both cases and controls in 2 studies. Thus, we excluded these studies from further analysis about serum levels [25] [26] [27] .
Data Analysis
We performed a meta-analysis of the mean differences of trace element levels in cases and controls on the basis of data extracted from the abovementioned studies, using a random-effect model to account for possible study heterogeneity (assessed with the I 2 statistic). We computed a weighted mean difference (WMD) with corresponding 95% CI of serum/plasma, whole blood, and CSF levels of selenium, copper, iron, and zinc. We also assessed publication bias by using funnel plots according to each biomarker of exposure. We carried out all statistical analyses with the Stata-15.1 package, by using the "metan" routine (Stata Corp., TX 2019).
Results
We originally identified a total number of 555 articles through PubMed/Medline. From these, we excluded 475 studies which, after title and abstract screening, Neuroepidemiology 2020;54:1-23 DOI: 10.1159/000502357 were not relevant ( Fig. 1) . After a full-text evaluation of the remaining papers, we excluded 19 more papers for the reasons reported in Figure 1 . We also excluded repeated or overlapping publications, by removing the earliest or the most incomplete ones [28] [29] [30] [31] [32] [33] [34] [35] [36] . We eventually selected 61 case-control studies for the present review (Table 1) . These studies reported mean trace element levels in specimens such as whole blood (n = 2), plasma and serum (n = 50), red blood cells (n = 2), hair (n = 1), and CSF (n = 14). Of these, 56 studies could be included in our meta-analysis, while the remaining 5 were only used in narrative synthesis. For selenium, we retrieved data on 588 cases and 721 controls (based on 3 studies on CSF and 11 on serum/plasma); for copper, 2,190 cases and 2,522 controls (10 studies on CSF and 28 on serum/plasma); for iron, 2,956 cases and 3,469 controls (12 studies on CSF, 32 on serum/plasma, and 2 on whole blood); for zinc, 1,798 cases and 1,913 controls (7 studies on CSF and 21 on serum/plasma). Overall, these studies were published between 1967and 2019 and carried out in different countries: 43% in Europe (n = 24, of which 9 in Italy and 5 in Spain), 37% in Asia (n = 21, of which 7 in India and 7 in China), and 20% in America (n = 11, 7 in the United States and 5 in South America).
Most studies reported age and sex of study subjects, while disease duration was available only in 29 of the 61 studies considered in the descriptive analysis reported in Table 1 and disease severity in 19 studies. Two studies assessed serum iron levels [15] and copper levels [37] only in men, while the remaining ones evaluated trace elements in both sexes. 
Selenium
We could analyze data from 12 studies ( Table 2) . For serum/plasma selenium concentrations, there was almost no difference between the weighted average levels in cases and controls (WMD -0.22 µg/L, 95% CI -8.05 to 7.62), while selenium concentrations in the CSF were considerably higher in patients (+ 51.6%), based on 3 studies (WMD +5.49 µg/L, 95% CI 2. 82-8.15 ). There was little evidence of publication bias (online suppl. Fig.  S1 ). Heterogeneity for serum/plasma selenium levels was very high (98.1%), while for studies based on CSF levels it amounted to 60.3% (Fig. 2) . Average selenium levels across the studies were substantially similar, apart from 2 old Spanish studies [38, 39] and a more recent study [22] , showing much lower concentrations. Copper As shown in Table 2 , average CSF copper concentrations were slightly higher (+4.5%) in patients than in controls (WMD +1.87, 95% CI -3.59 to 7.33), whereas serum/plasma copper levels were slightly lower in patients (-4.5%, WMD -42.79, 95% CI -134.35 to 48.76 - Fig. 3 ). Some slight evidence of publication bias emerged, as shown in online Supplementary Figure S1 . Heterogeneity was very high in both analyses (I 2 = 99.7 and 96.5% for serum/plasma and CSF levels, respectively, Fig. 3 ). Average copper concentrations measured in CSF varied considerably across studies, while copper mean levels in se-rum/plasma were considerably more similar. Results did not substantially change when we restricted the analysis to earlier PD cases only, as reported in 2 studies [40, 41] with serum/plasma WMD -39.54 (95% CI -131.22 to 52.14 and CSF WMD 2.01, 95% CI -3.34 to 7.35; online suppl. Fig. S2 ).
Iron
Based on 33 studies, iron levels in plasma or serum were slightly lower in patients (-5.7%; WMD -58.19 µg/L, 95% CI -106.49 to -9.89), and this was also true for whole blood concentrations as reported in 2 studies (-10.8%; Table 2 and Fig. 4 ). Conversely, CSF iron content was slightly higher (+9.5%) in patients compared with controls (WMD 9.92 µg/L, 95% CI 1.23-18.61). By repeating the analysis restricted to patients with shorter duration PD in 1 study [41] , results changed little (serum/plasma WMD -55.31, 95% CI -103.38 to -7.24; online suppl. Fig. S3 ). High heterogeneity characterized both studies based on serum or plasma levels (I 2 = 95.6%) and those reporting CSF levels (I 2 = 95.0%), but not those analyzing whole blood concen- (Fig. 4 ). Some asymmetry in funnel plot suggested some publication bias in favor of lower trace element levels in patients for studies based on CSF, while there was little indication of such bias for studies on serum/plasma iron levels (online suppl. Fig. S1 ). Average iron concentrations did not differ between PD patients and controls across most studies, with the exception of 4 studies for CSF levels [21, 27, 42, 43] and 2 for serum/plasma mean concentrations [44, 45] .
Zinc
In the 24 studies investigating this trace element, average zinc levels were lower in PD cases than in controls, both in CSF (-10.8%; WMD -7.34, 95% CI:-14.82 to 0.14) and serum/plasma (-7.5%; WMD -79.93, 95% CI -143.80 to -16.06), as shown in Table 2 . No study investigated zinc levels in whole blood. The heterogeneity of results was 95.1% in studies examining CSF levels and 98.1% for those based on plasma/serum concentrations (Fig. 5 ). By repeating the analysis restricted to patients with shorter duration PD in 1 study [41] , results did not change substantially (online suppl. Fig. S4 ). Some evidence of publication bias in favor of lower levels in PD patients emerged for both serum/plasma and CSF matrices (online suppl. Fig. S1 ).
Sensitivity Analyses
Some studies allowed to compare trace element levels in patients with recent PD diagnosis compared with those with longer disease duration ( Table 3 and Fig. 6 ). Gellein et al. [46] detected higher serum trace element levels in 19 PD subjects sampled few months to few years before PD diagnosis, compared with values detected in the same patients several years (4-12 years) after disease diagnosis, particularly for selenium and to a lesser extent for iron, copper, and zinc. Two of the 5 studies that analyzed copper serum levels in patients with different PD clinical duration found higher levels in patients with longer disease duration [19, 20] , while 2 other studies found lower concentrations in this subgroup [24, 40, 41] . Takahashi et al. [24] compared trace element concentrations in PD patients with recent PD diagnosis (disease duration 2.0 ± 1.3 years) with those detected in patients with longer disease duration (6.0 ± 4.6 years), finding lower levels of selenium, copper, and zinc in patients with longer PD clinical course, while iron serum concentrations were higher. Hegde et al. [41] found lower levels of iron and zinc in patients with long-term illness, both in serum/plasma and CSF.
Discussion
In this systematic review and meta-analysis, we summarized the results of case-control studies comparing levels of selenium, copper, iron and zinc in patients with PD and controls in different biological matrices. To the best of our knowledge, this is the first meta-analysis assessing biomarkers of selenium levels and PD. We found similar selenium exposure in the serum or plasma of PD patients compared with controls, while CSF levels were consider-ably higher in PD patients. Such increased CSF selenium contents may either suggest that selenium overexposure in the central nervous system plays a role in disease etiology or indicate the occurrence of selective derangements of the trace element status as a consequence of disease onset and progression. The possible causal association between increased selenium exposure and PD risk is also supported by recent epidemiological findings showing an excess PD mortality in individuals exposed to selenium in its inorganic hexavalent form through drinking water [47] . Although conflicting evidence has been reported by nonhuman studies on the involvement of selenium in PD etiology [48] , there is biological plausibility for such association. Selenium is a nutritionally essential element in the human owing to several properties such as its antioxidant activity, regulation of Ca 2+ channels, and modulation of neurogenesis [49] . Nevertheless, selenium may also exert many adverse effects on several body systems including the central nervous system, encompassing the induction of oxidative stress and other mechanisms [50] [51] [52] [53] [54] . In particular, selenium might adversely affect dopaminergic neurons, since selenium overexposure may lead to neurodegeneration through the generation of reactive oxygen species and the alteration of mRNA expression of dopamine receptors, tyrosine hydroxylase, and dopamine transporter genes [55] [56] [57] [58] [59] . Selenium neurotoxicity may occur even at very low levels [60, 61] , and it has been shown that this element activates the p38 pathway [62] , a mechanism implicated in PD etiopathogenesis [63] . Concerning copper and iron, we updated previous reviews by adding 9 and 18 studies, respectively [64, 65] . Differently from previous reviews that could not identify appreciable differences between element levels in PD cases and controls, we found higher CSF levels in PD cases, while levels were lower in serum, plasma, and whole blood. A potential relevance of both copper and iron elements in PD etiopathogenesis has been reported by many investigators, including neurotoxic effects that may occur through different mechanisms [66] [67] [68] . Dusek et al. [69] suggested that iron metabolism dysregulation in substantia nigra is related to neurodegeneration. More recently, a synergistic mechanism between copper and iron has been suggested, with evidence for an interaction of these elements with α-synuclein [11, [70] [71] [72] [73] . Copper and iron, such as other redox active metals, may also affect protein aggregation through the generation of free oxygen radicals [74, 75] . In addition, impaired distribution of iron may lead to brain damage, and excess iron in the brain is a hallmark of neurodegenerative disorders such as Alzheimer's disease and amyotrophic lateral sclerosis [76] [77] [78] [79] .
In PD patients, selenium, copper, and iron all showed higher levels in CSF, but lower ones in serum/plasma or whole blood compared with controls. Such different findings for the same elements were not entirely unexpected. In fact, it has been shown that CSF trace element levels and their corresponding peripheral, circulating levels may not correlate, particularly in subjects with PD and other neurodegenerative diseases often related to impaired nutritional status [80] [81] [82] . In particular, alteration of metal transporters and/or alterations in blood-brain barrier may occur in these patients, affecting the CSF/ blood ratio of trace elements [83] [84] [85] . Lack of correlation between CSF and blood trace element levels may also stem from peculiarities in CNS detoxification system [86] . For selenium, some of its species, namely the inorganic ones, did not correlate between blood and CSF in healthy subjects, differently from the organic chemical forms [87, 88] .
In terms of biological relevance and etiologic significance, we consider CSF trace element levels of higher importance than the blood ones. CSF is a biological matrix secreted by the central nervous system and forms an integral part of it, thus becoming highly relevant to the diagnosis of neurodegenerative diseases [89] [90] [91] including PD [92] . CSF is directly connected, without a barrier, to the extracellular space of brain parenchyma and facilitates molecular exchange. The composition of CSF and extracellular brain fluids is similar, and a misbalance or exposure and depletion of elements in the brain are reflected by CSF [93] . The importance of element levels in CSF as a biomarker of central nervous system exposure, compared with indicators in peripheral matrices such as serum/plasma or whole blood, is widely appreciated, also reflecting metabolic processes underlying brain parenchyma functioning [87, 94] . Therefore, under an etiologic perspective, the increased trace element contents in the CSF of PD patients compared with controls are more important than the opposite findings for serum/plasma levels of these trace elements. In fact, the exposure within the central nervous system may be considered most relevant to PD (or more generally to neurodegenerative diseases) etiology, compared with peripheral exposure. This is particularly true for selenium, which showed by far the highest percent increase in CSF levels compared with the other trace elements tested. Conversely, no change in blood levels was detected, emphasizing how poorly this biomarker may mirror central nervous system exposure.
When assessing average trace element levels according to PD clinical duration, we generally observed lower levels in patients with longer-term illness, suggesting that PD progression is associated with a reduction of circulating trace element levels. This means that the higher CSF levels of these elements, and particularly of selenium, that we found in our meta-analysis are more likely to be involved in the causal pathway of the disease than to be an effect of disease itself. Alternatively, higher CSF levels may simply predict or accompany disease onset. Conversely, the low trace element levels detected in overall PD patients or in those selectively having a long clinical course are likely to be a consequence of disease itself, due to either an impaired nutritional status [80] [81] [82] or an alteration of trace element metabolism due to disease progression. Some studies assessed trace elements intake through diet in relation with PD risk, yielding inconsistent results though with some indication of a positive association with iron intake [95, 96] . It is also possible that the increased CSF selenium contents may be a consequence of the increased synthesis of selenoproteins, enzymes with antioxidant properties, in the central nervous system, as a compensatory response to increased reactive oxygen species production [97] . This might also lead to a concomitant reduction in blood selenium contents. However, a better understanding of the mechanisms underpinning selenium changes in the central nervous system before and during PD is hampered by lack of data on changes of CSF selenium content according to disease duration. Overall, the findings for the other elements in both Neuroepidemiology 2020;54:1-23 DOI: 10.1159/000502357 CSF and blood, and for selenium in blood, appear to confirm an etiologic role of high exposure to selenium, though less strongly to iron and copper, in PD etiology.
Based on 24 studies (a double number of the previous meta-analysis), we found lower zinc concentrations in both CSF and blood of PD patients, consistently with a possible role of zinc deficiency in disease etiopathogenesis. Our findings mirror those of a recent meta-analysis that evaluated the association between zinc serum levels and PD [98] . These results are of interest in light of role of zinc as an antioxidant enzyme cofactor, the increased oxidative stress following decreased zinc levels [99] [100] [101] [102] , and finally the observation that zinc supplements may improve PD severity in animal models [103] . Recent studies have underlined the key role of dysregulation of zinc concentration and its synergic interaction with dopaminergic system in both cells and animal models [104, 105] . However, the observation that zinc levels inversely correlated with PD duration in the few studies assessing such association raises the possibility of reverse causation, that is, of an effect of disease itself in decreasing zinc status. This suggests caution in hypothesizing that zinc deficiency may be a risk factor, and not a consequence, of PD.
We must acknowledge some limitations in the reviewed studies and in the results of this meta-analysis. First, particularly for some elements and matrices, the number of studies and their size were too low to yield a satisfactory statistical precision of the summary effect estimates, as shown by their wide confidence intervals. In addition, in several studies some relevant details of study population were lacking, such as PD duration and clinical severity in patients. Moreover, all studies we retrieved were case-control, a study design that may induce spurious associations from an etiological point of view. In fact, reverse causation is a key issue in assessing the etiological role of trace elements, as recently shown for selenium in Alzheimer's dementia by comparing the case-control with the longitudinal study design [106] . A further limitation also was that some reviewed studies included a control population who might not have been completely appropriate. In fact, they had undergone sample analysis because of some neurological symptoms, in turn possible related to trace element alterations and to potential selection bias. As previously mentioned, finally, no speciation analysis was available in the studies reviewed. This is a major limitation in light of what we know from the few available speciation studies on central nervous system disease, showing the relevance of the chemical forms of elements such as selenium or iron, and how speciation analysis may lead to entirely different results in the same study [89, 91, 107] . Nowadays, elemental speciation fosters important links between powerful techniques, from analytical chemistry to neurodevelopment or brain degeneration research [50] . Element speciation analysis has matured to provide key knowledge by investigating changes in both species concentration and the pattern of essential elements (e.g., SELENOP vs. Se [IV]) [89] , or shifts in their redox pairs (e.g., Fe [II] vs. Fe [III] [108] ). As such, it would definitively allow for deeper insights into the molecular mechanisms and pathways of PD. It would therefore be of fundamental importance to confirm and expand the scope of our study, by performing elemental speciation analysis for selenium as well as the other trace elements [89, 108] .
In conclusion, our meta-analysis indicates that, despite their lower peripheral circulating trace element levels, PD patients exhibit higher levels of copper, iron, and particularly selenium in CSF compared with referents. Such higher exposure might be a risk factor of PD, rather than a consequence of the disease, consistent with the biological plausibility of these associations. This seems to be particularly true for selenium, given some recent epidemiological and toxicological evidence on how its species may adversely affect dopamine metabolism. The decreased zinc levels found in PD patients also deserve careful scrutiny, since it might indicate a role of zinc deficiency in disease etiology, though we could not entirely rule out the possibility of reverse causation about this finding.
